Development of chronic pain in males with traumatic spinal cord injury: role of circulating levels of the chemokines CCL2 and CXCL10 in subacute stage.
Journal
Spinal cord
ISSN: 1476-5624
Titre abrégé: Spinal Cord
Pays: England
ID NLM: 9609749
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
14
10
2018
accepted:
11
05
2019
revised:
31
03
2019
pubmed:
12
6
2019
medline:
1
5
2020
entrez:
12
6
2019
Statut:
ppublish
Résumé
Longitudinal study. To assess the impact of spinal cord injury (SCI) on circulating levels of chemokines (CCL2 and CXCL10) and its relation with pain development. National Hospital for SCI patients. We longitudinally studied changes in the circulating levels of CCL2 and CXCL10 in 27 male patients with complete SCI who were evaluated in the early subacute phase and indeed 3 and 6 months after injury measuring at each time-point serum levels of CCL2 and CXCL10. Patients were telephonically interviewed about pain 1 year after SCI. In the early subacute phase, patients with pain showed higher CXCL10 and similar CCL2 levels as opposed to those without pain. Moreover, CCL2 concentrations were positively associated with pain intensity. The results obtained by analysing the temporal profile of the chemokines suggested that CXCL10 was inclined to decrease over time, while CCL2 increased over time. The results of this preliminary study, the first performed in humans with traumatic SCI, suggest a link between changes in the circulating chemokine profile and pain development in subacute SCI stage as well as with severity in a more chronic stage. Large series studies will evaluate whether the circulating chemokine status can be useful as a biomarker for assessing the patients' risk for pain development.
Identifiants
pubmed: 31182785
doi: 10.1038/s41393-019-0311-3
pii: 10.1038/s41393-019-0311-3
doi:
Substances chimiques
Biomarkers
0
CCL2 protein, human
0
CXCL10 protein, human
0
Chemokine CCL2
0
Chemokine CXCL10
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
953-959Références
J Neurochem. 2008 Jul;106(2):757-69
pubmed: 18419759
Phys Med Rehabil Clin N Am. 2014 Aug;25(3):505-17, vii
pubmed: 25064785
Arch Phys Med Rehabil. 1998 Jan;79(1):81-6
pubmed: 9440423
Brain Res Rev. 2009 Apr;60(1):125-34
pubmed: 19146875
J Neurosci. 2008 May 14;28(20):5189-94
pubmed: 18480275
Sci STKE. 2004 Sep 21;2004(252):reE14
pubmed: 15454629
Glia. 2008 Jun;56(8):888-94
pubmed: 18338796
Breast Cancer Res Treat. 2014 Jan;143(2):255-63
pubmed: 24337539
Nat Neurosci. 2002 Nov;5 Suppl:1062-7
pubmed: 12403987
Pain Med. 2010 Jul;11(7):1037-43
pubmed: 20492574
J Immunol. 2005 Oct 15;175(8):5370-8
pubmed: 16210643
Rheumatology (Oxford). 2008 Jan;47(1):45-9
pubmed: 18077490
Neurosci Lett. 2004 May 6;361(1-3):184-7
pubmed: 15135924
Mt Sinai J Med. 1991 May;58(3):191-202
pubmed: 1875956
J Neurosci. 2008 Nov 12;28(46):11792-5
pubmed: 19005041
J Neurosci. 2011 Apr 13;31(15):5865-75
pubmed: 21490228
J Neurophysiol. 2006 Nov;96(5):2189-99
pubmed: 16775210
Neuroscience. 2007 Nov 9;149(3):706-14
pubmed: 17870246
CNS Drugs. 2011 Nov 1;25(11):971-81
pubmed: 22054120
Neuron. 2012 Feb 23;73(4):638-52
pubmed: 22365541
Trends Immunol. 2005 Oct;26(10):529-34
pubmed: 16099720
Spinal Cord. 2017 Jun;55(6):570-574
pubmed: 28117331
Obesity (Silver Spring). 2017 Mar;25(3):600-607
pubmed: 28164479
J Neurosci. 2003 Apr 1;23(7):3028-38
pubmed: 12684490
J Neuroimmunol. 2008 Jul 31;198(1-2):69-74
pubmed: 18538419
Neurosurg Focus. 2008;25(5):E2
pubmed: 18980476
Spinal Cord. 2005 May;43(5):278-82
pubmed: 15570317
Nat Clin Pract Neurol. 2006 Feb;2(2):95-106
pubmed: 16932531
J Surg Res. 2012 Jul;176(1):293-300
pubmed: 21962809